高剂量巴氯芬对接受机械通气的有害酒精使用患者激越相关事件的影响:一项随机临床试验
这项在法国18个ICU开展的3期双盲安慰剂对照随机临床试验,纳入314例接受机械通气且符合有害酒精使用标准的成人患者,比较巴氯芬(n=159,按估算肾小球滤过率调整50–150 mg/d)与安慰剂(n=155)在机械通气期间至多15天的作用。主要终点为治疗期间至少发生1次激越相关事件的患者百分比,巴氯芬组显著低于安慰剂组(19.7% vs 29.7%;差值-9.93%[95%CI -19.45%至-0.42%];校正OR 0.59[95%CI 0.35-0.99])。巴氯芬组机械通气中位时间(9 vs 8天)和ICU停留时间(14 vs 11天)显著延长,28天死亡率无显著差异(25.3% vs 21.6%;校正OR 1.24[95%CI 0.72-2.13]),延迟觉醒更常见(8.9% vs 1.9%)。作者认为效应有限且需进一步研究确定巴氯芬在此场景中的可能作用并优化剂量。
要点
- 主要终点:巴氯芬组19.7%(31/159)vs 安慰剂组29.7%(46/155)至少发生1次激越相关事件,差值-9.93%(95%CI -19.45%至-0.42%),校正OR 0.59(95%CI 0.35-0.99)。
- 巴氯芬组机械通气中位时间9天 vs 安慰剂组8天(差值2.00[95%CI 0.00-3.00];拔管HR 0.76[95%CI 0.60-0.97]),ICU停留14天 vs 11天(差值2.00[95%CI 0.00-4.00];出ICU HR 0.70[95%CI 0.54-0.90])。
- 28天死亡率巴氯芬组25.3% vs 安慰剂组21.6%,校正OR 1.24(95%CI 0.72-2.13),无显著差异。
- 延迟觉醒(停用镇静镇痛药后72小时无睁眼)巴氯芬组14例(8.9%)vs 安慰剂组3例(1.9%)。
- 作者认为效应有限,结合次要终点和不良事件总体结果,需进一步研究确定巴氯芬在此场景中的可能作用并优化剂量。
适用人群与场景
- 接受机械通气且符合有害酒精使用标准的成人患者,来自法国18个ICU。
- 纳入时间2016年6月至2018年2月,末次随访2019年5月;平均年龄57岁,女性60例(17.2%)。
处置流程与药物剂量
- 巴氯芬组(n=159):根据估算肾小球滤过率调整剂量,50–150 mg/d,机械通气期间使用至最多15天,随后经3–6天逐渐减量。
- 安慰剂组(n=155):同法给予安慰剂。
红旗征与不能漏的情况
- 延迟觉醒(停用镇静药和镇痛药后72小时无睁眼)在巴氯芬组发生14例(8.9%),安慰剂组3例(1.9%)。
研究设计与关键结果
- 研究类型:3期双盲安慰剂对照随机临床试验,18个ICU,随机314例(巴氯芬n=159,安慰剂n=155),313例(99.7%)完成试验。
- 主要终点:治疗期间至少1次激越相关事件的患者百分比,巴氯芬组31例(19.7%)vs 安慰剂组46例(29.7%);差值-9.93%(95%CI -19.45%至-0.42%);校正OR 0.59(95%CI 0.35-0.99)。
- 18个预设次要终点中14个无显著差异。
- 机械通气中位时间:巴氯芬组9天 vs 安慰剂组8天;差值2.00(95%CI 0.00-3.00);拔管HR 0.76(95%CI 0.60-0.97)。
- ICU停留中位时间:巴氯芬组14天 vs 安慰剂组11天;差值2.00(95%CI 0.00-4.00);出ICU HR 0.70(95%CI 0.54-0.90)。
- 28天死亡率:巴氯芬组25.3% vs 安慰剂组21.6%;校正OR 1.24(95%CI 0.72-2.13),无显著差异。
- 延迟觉醒(停用镇静药和镇痛药后72小时无睁眼):巴氯芬组14例(8.9%)vs 安慰剂组3例(1.9%)。
证据类型、等级与局限
- 证据类型:3期、双盲、安慰剂对照随机临床试验。
- 试验注册号:ClinicalTrials.gov NCT02723383。
- 局限:作者指出效应有限,结合次要终点和不良事件的总体结果,需进一步研究确定巴氯芬在此场景中的可能作用并优化剂量。
对床旁实践的改变
- 在接受机械通气的有害酒精使用患者中,高剂量巴氯芬较安慰剂显著减少至少1次激越相关事件(19.7% vs 29.7%),但机械通气和ICU停留时间延长,28天死亡率无显著差异。
- 作者认为,鉴于效应有限及次要终点和不良事件的总体结果,需进一步研究确定巴氯芬在此场景中的可能作用并优化剂量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Unhealthy alcohol use can lead to agitation in the intensive care unit (ICU).
OBJECTIVE: To assess whether high-dose baclofen reduces agitation-related events compared with placebo in patients with unhealthy alcohol use receiving mechanical ventilation.
DESIGN, SETTINGS, AND PARTICIPANTS: This phase 3, double-blind, placebo-controlled, randomized clinical trial conducted in 18 ICUs in France recruited adults receiving mechanical ventilation who met criteria for unhealthy alcohol use. Patients were enrolled from June 2016 to February 2018; the last follow-up was in May 2019.
INTERVENTIONS: Baclofen (n = 159), adjusted from 50 to 150 mg per day based on estimated glomerular filtration rate, or placebo (n = 155) during mechanical ventilation up to a maximum of 15 days before gradual dose reduction over 3 to 6 days.
MAIN OUTCOMES AND MEASURES: The primary end point was the percentage of patients with at least 1 agitation-related event over the treatment period. Secondary outcomes included duration of mechanical ventilation, length of ICU stay, and 28-day mortality.
RESULTS: Among 314 patients who were randomized (mean age, 57 years; 60 [17.2%] women), 313 (99.7%) completed the trial. There was a statistically significant decrease in the percentage of patients who experienced at least 1 agitation-related event in the baclofen group vs the placebo group (31 [19.7%] vs 46 [29.7%]; difference, -9.93% [95% CI, -19.45% to -0.42%]; adjusted odds ratio, 0.59 [95% CI, 0.35-0.99]). Of 18 prespecified secondary end points, 14 were not significantly different. Compared with the placebo group, the baclofen group had a significantly longer median length of mechanical ventilation (9 vs 8 days; difference, 2.00 [95% CI, 0.00-3.00]; hazard ratio [HR] for extubation, 0.76 [95% CI, 0.60-0.97]) and stay in the ICU (14 vs 11 days; difference, 2.00 [95% CI, 0.00-4.00]; HR for discharge, 0.70 [95% CI, 0.54-0.90]). At 28 days, there was no significant difference in mortality in the baclofen vs placebo group (25.3% vs 21.6%; adjusted odds ratio, 1.24 [95% CI, 0.72-2.13]). Delayed awakening (no eye opening at 72 hours after cessation of sedatives and analgesics) occurred in 14 patients (8.9%) in the baclofen group vs 3 (1.9%) in the placebo group.
CONCLUSIONS AND RELEVANCE: Among patients with unhealthy alcohol use receiving mechanical ventilation, treatment with high-dose baclofen, compared with placebo, resulted in a statistically significant reduction in agitation-related events. However, considering the modest effect and the totality of findings for the secondary end points and adverse events, further research is needed to determine the possible role of baclofen in this setting and to potentially optimize dosing.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02723383.
参考来源
- Vourc'h M, Garret C, Gacouin A, et al. Effect of High-Dose Baclofen on Agitation-Related Events Among Patients With Unhealthy Alcohol Use Receiving Mechanical Ventilation: A Randomized Clinical Trial. JAMA. 2021. PMID: 33620407. doi:10.1001/jama.2021.0658
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。